TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report

TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report

Epithelioid glioblastoma (EGBM, classified as glioblastoma, IDH wild type, grade 4 according to the fifth edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) (WHO CNS5)) is a highly aggressive malignancy, with a median progression-free survival...

Full description

Bibliographic Details
Main Authors:	Yuxuan Ding, Qiang Wang, Feijiang Wang, Nan Wu, Jianrui Li, Xia He, Hao Pan, Lijun Wang
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	Brain Sciences
Subjects:	glioblastoma case report epithelioid glioblastoma tumor-treating fields (TTFields) genetic diagnosis BRAF V600E
Online Access:	https://www.mdpi.com/2076-3425/13/4/633

Similar Items

First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis
by: Rebecca Kassubek, et al.
Published: (2022-04-01)

Epithelioid glioblastoma exhibits a heterogeneous molecular feature: A targeted next-generation sequencing study
by: Rui Pan, et al.
Published: (2022-11-01)

Dexamethasone and compliance affect TTFields efficacy to glioblastoma patients: a systematic review and meta-analysis
by: Shupeng Li, et al.
Published: (2022-09-01)

Less‐invasive diagnosis of disseminated epithelioid glioblastoma harboring BRAF V600E mutation by cerebrospinal fluid analysis—A case report
by: Manabu Natsumeda, et al.
Published: (2021-07-01)

Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial
by: N. Guberina, et al.
Published: (2020-04-01)

A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights
by: Li Xing, et al.
Published: (2023-09-01)

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
by: Mario E. Lacouture, et al.
Published: (2020-07-01)

Tumor-Treating Fields in Glioblastomas: Past, Present, and Future
by: Xiaopeng Guo, et al.
Published: (2022-07-01)

Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
by: Zvi Ram, et al.
Published: (2022-04-01)

Erratum: Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
by: Frontiers Production Office
Published: (2022-06-01)

Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression
by: Chirag B. Patel, et al.
Published: (2021-01-01)

Dimorphic glioblastoma with glial and epithelioid phenotypes: Clonal evolution and immune selection
by: Mark Willy L. Mondia, et al.
Published: (2023-01-01)

Abnormal Schwannoma-like Growth of multiple, multifocal BRAF V600E-positive Glioblastoma in the Interior Acoustic Canal with Leptomeningeal Infiltration: a case report
by: Roopa Jayarama-Naidu, et al.
Published: (2022-02-01)

Glioblastoma-Derived Three-Dimensional Ex Vivo Models to Evaluate Effects and Efficacy of Tumor Treating Fields (TTFields)
by: Vera Nickl, et al.
Published: (2022-10-01)

Epithelioid glioblastoma presenting as aphasia in a young adult with ovarian cancer: A case report
by: Megan M. Finneran, et al.
Published: (2019-04-01)

Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity
by: Callum G. Jones, et al.
Published: (2024-02-01)

Patient Reported Outcome (PRO) Among High-Grade Glioma Patients Receiving TTFields Treatment: A Two Center Observational Study
by: Julia Onken, et al.
Published: (2019-10-01)

Diagnostic challenges in epithelioid glioblastoma of the cerebellum: A case report
by: Phiza Aggarwal, et al.
Published: (2021-01-01)

Tumor-Treating Fields Therapy for Pediatric Brain Tumors
by: Atsushi Makimoto, et al.
Published: (2021-04-01)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
by: George Ansstas, et al.
Published: (2016-01-01)

Case Report of Complete Radiological Response of a Thalamic Glioblastoma After Treatment With Proton Therapy Followed by Temozolomide and Tumor-Treating Fields
by: Marco Stein, et al.
Published: (2020-04-01)

Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study
by: Felix Bokstein, et al.
Published: (2020-04-01)

Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
by: Guangrong Lu, et al.
Published: (2019-01-01)

Guidelines for Burr Hole Surgery in Combination With Tumor Treating Fields for Glioblastoma: A Computational Study on Dose Optimization and Array Layout Planning
by: Fang Cao, et al.
Published: (2022-06-01)

In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso
by: Roni Blatt, et al.
Published: (2021-06-01)

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
by: Ryan Miller, et al.
Published: (2022-04-01)

Glioblastoma in an old patient treated with a combination of tumor-treating fields and standard chemoradiotherapy: A case report
by: Yiting Yang, et al.
Published: (2023-01-01)

Progress on TTFields combined with other therapies for glioblastoma treatment: A narrative review
by: Yong Cao, et al.
Published: (2022-01-01)

Oncogenic BRAF Alterations and Their Role in Brain Tumors
by: Felix Behling, et al.
Published: (2019-06-01)

Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma <i>In Vitro</i> and <i>In Vivo</i>
by: Shiri Davidi, et al.
Published: (2022-06-01)

Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas
by: Dietmar Krex, et al.
Published: (2023-03-01)

Multidisciplinary Therapy Managed Recurrent Glioblastoma in a BRAF-V600E Mutant Pregnant Female: A Case Report and Review of the Literature
by: Chaoying Qin, et al.
Published: (2020-09-01)

Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region
by: Milan J. Anadkat, et al.
Published: (2023-01-01)

Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
by: Azadeh Ebrahimi, et al.
Published: (2022-01-01)

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
by: Vasu Munjapara, et al.
Published: (2022-10-01)

Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro, and safety for application to COVID-19 patients in a pilot clinical study
by: Avraham Abutbul, et al.
Published: (2023-11-01)

Gingival epithelioid haemangioendothelioma: A case report
by: Yonglian Wu, et al.
Published: (2022-07-01)

Postoperative extracranial metastasis from glioblastoma: a case report and review of the literature
by: Wenjiao Wu, et al.
Published: (2017-12-01)

Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data
by: Stewart Goldman, et al.
Published: (2022-07-01)

Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood–Brain Barrier In Vitro and In Vivo
by: Ellaine Salvador, et al.
Published: (2022-09-01)